Why insider trading matters?

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

- Peter Lynch
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Sector: Healthcare; Industry: Biotechnology

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company was founded in 2009 and is based in Norwood, Massachusetts.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-12-21 Moran Sean F. Chief Financial Officer Sell 141,110 $1.62 $228,179 Yes
2020-12-16 Moran Sean F. Chief Financial Officer Sell 36,923 $1.32 $48,628 Yes
2020-11-11 Cohen Yuval Chief Executive Officer Buy 4,240 $1.21 $5,126 No
2020-03-17 Millian Craig Stuart Chief Commercial Officer Buy 2,000 $4.25 $8,500 No
2020-03-17 Discordia Robert Paul Chief Operating Officer Buy 2,840 $3.54 $10,054 No
2020-03-17 White Barbara Chief Medical Officer Buy 15,606 $3.63 $56,650 No
2020-03-17 Cohen Yuval Chief Executive Officer Buy 4,300 $3.49 $15,007 No
2019-11-12 White Barbara Chief Medical Officer Buy 3,424 $4.38 $14,992 No
2019-11-12 Cohen Yuval Chief Executive Officer Buy 1,430 $4.26 $6,092 No
2019-11-11 Millian Craig Stuart Chief Commercial Officer Buy 1,000 $4.38 $4,380 No
2019-11-11 Discordia Robert Paul Chief Operating Officer Buy 2,500 $4.62 $11,558 No
2019-08-15 Millian Craig Stuart Chief Commercial Officer Buy 1,500 $5.48 $8,213 No
2019-08-12 White Barbara Chief Medical Officer Buy 1,639 $6.10 $9,998 No
2019-08-12 Millian Craig Stuart Chief Commercial Officer Buy 1,500 $6.00 $9,000 No
2019-08-12 Cohen Yuval Chief Executive Officer Buy 1,175 $6.06 $7,116 No
2019-08-12 Discordia Robert Paul Chief Operating Officer Buy 15,000 $5.86 $87,894 No
2019-05-17 White Barbara Chief Medical Officer Buy 1,389 $7.20 $10,001 No
2019-05-14 Millian Craig Stuart Chief Commercial Officer Buy 1,000 $7.23 $7,227 No
2019-05-14 Moran Sean F. Chief Financial Officer Buy 100 $7.12 $712 No
2019-05-13 Cohen Yuval Chief Executive Officer Buy 995 $6.99 $6,955 No
2019-03-15 Hochman David P Director Buy 2,000 $6.98 $13,958 No
2019-03-15 Jenkins John Kenneth Director Buy 1,000 $6.98 $6,978 No
2019-03-14 Millian Craig Stuart Chief Commercial Officer Buy 5,000 $6.85 $34,258 No
2019-03-14 White Barbara Chief Medical Officer Buy 4,638 $6.47 $29,994 No
2019-03-14 Moran Sean F. Chief Financial Officer Buy 1,500 $6.67 $10,005 No
2019-03-14 Cohen Yuval Chief Executive Officer Buy 1,530 $6.49 $9,930 No
2018-05-15 White Barbara Chief Medical Officer Buy 2,586 $5.87 $15,174 No
2018-05-15 Cohen Yuval Chief Executive Officer Buy 1,725 $5.85 $10,091 No
2018-05-14 Hochman David P Director Buy 5,000 $5.47 $27,375 No
2018-05-15 Moran Sean F. Chief Financial Officer Buy 4,000 $5.77 $23,080 No

Insider Smart

MGM Resorts International (MGM) - If we were to pick one of the easy trade from the crash, it has to be MGM, checkout the impressive insider buying after crash. Do you really need more confidence to pull the trigger? That's the mental edge you need to work against fear.

Insider Smart

Edesa Biotech, Inc. (EDSA) - President and CEO bought shares of EDSA in late May around $3, two weeks after their purchase, the stock jump to $9, very well timed buy.